Photo: Jeffrey Coolidge/Getty Images

The Federal Trade Commission has warned 7 law firms and marketing companies that their TV ads alleging harm, and offering possible monetary relief, from certain prescription drugs "may be deceptive or unfair" and may prompt people to stop taking their medications.

Driving the news: Documents obtained by Axios under the Freedom of Information Act show the FTC was particularly concerned about personal injury ads against the diabetes drugs Invokana and Invokamet.

Between the lines: The FTC is worried these types of ads — such as this from Ketterer Browne & Anderson and this from Amicus — are confusing people into thinking the medications have been recalled or that the federal government has issued formal "medical alerts" even though that's not the case.

  • 6 of the 7 firms that received FTC letters last month had ads warning people about Invokana or Invokamet.
  • Other drugs mentioned in the allegedly deceptive TV ads were Abilify, Tasigna, Xarelto, Pradaxa and Nexium, among others.

The other side: Axios reached out to all 7 law firms and marketers. Travis Marble of Lucy Business Services, which advertises legal services on behalf of firms, said he had no comment since the matter is pending. The others did not immediately provide an interview or comments.

The bottom line: Be wary of personal injury TV ads.

Go deeper: Read the FTC's letters.

Go deeper

BodyArmor takes aim at Gatorade's sports drink dominance

Illustration: Eniola Odetunde/Axios

BodyArmor is making noise in the sports drink market, announcing seven new athlete partnerships last week, including Christian McCaffrey, Sabrina Ionescu and Ronald Acuña Jr.

Why it matters: It wants to market itself as a worthy challenger to the throne that Gatorade has occupied for nearly six decades.

S&P 500's historic rebound leaves investors divided on future

Data: Money.net; Chart: Axios Visuals

The S&P 500 nearly closed at an all-time high on Wednesday and remains poised to go from peak to trough to peak in less than half a year.

By the numbers: Since hitting its low on March 23, the S&P has risen about 50%, with more than 40 of its members doubling, according to Bloomberg. The $12 trillion dollars of share value that vanished in late March has almost completely returned.

Newsrooms abandoned as pandemic drags on

Illustration: Sarah Grillo/Axios

Facing enormous financial pressure and uncertainty around reopenings, media companies are giving up on their years-long building leases for more permanent work-from-home structures. Others are letting employees work remotely for the foreseeable future.

Why it matters: Real estate is often the most expensive asset that media companies own. And for companies that don't own their space, it's often the biggest expense.